IP Library Granted Patent US 10,633,685
Granted Patent B2
US 10,633,685 · App. 15/511,565 · Granted Apr 28, 2020

Methods and materials for biosynthesis of mogroside compounds

Inventors: Jens Houghton-Larsen (Birkerod, DK); Katarzyna Krzystanek (Reinach, CH); Angelika Semmler (Copenhagen, DK); Iver Klavs Riishede Hansen (Copenhagen, DK); Soren Damkiaer (Reinach, CH); Yaoquan Liu (Palo Alto, CA); Jorgen Hansen (Frederiksberg, DK); Sathish Kumar (Tamil Nadu, IN); Muthuswamy Panchapagesa Murali (Chennai, IN); Nina Nicoline Rasmussen (Hvidovre, DK)
Assignee: EVOLVA SA
C12P33/00A23L27/36C07H1/06C12N9/0014C12N9/0042C12N9/0071C12N9/0073C12N9/1051C12N9/14C12N9/90C12N15/00C12P19/18C12P19/56A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,633,685
App. No.
15/511,565
Granted
Apr 28, 2020
Kind
B2
Abstract

Methods for recombinant and enzymatic production of mogroside compounds and compositions containing mogroside compounds are provided by this invention.

Claims (180)

1. A recombinant host cell capable of producing a mogrol precursor, a mogroside precursor, and/or a mogroside compound in a cell culture, comprising:

(a) a gene encoding a polypeptide capable of synthesizing oxidosqualene or dioxidosqualene from squalene;

wherein the polypeptide capable of synthesizing oxidosqualene or dioxidosqualene from squalene comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:54;

(b) a gene encoding a polypeptide capable of synthesizing cucurbitadienol from oxidosqualene, or 24,25-epoxy-cucurbitadienol from dioxidosqualene;

wherein the polypeptide capable of synthesizing cucurbitadienol from oxidosqualene or 24,25-epoxy-cucurbitadienol from dioxidosqualene comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:43;

(c) a gene encoding a polypeptide capable of synthesizing 11-hydroxy-cucurbitadienol from cucurbitadienol, or 11-hydroxy-24,25-epoxy-cucurbitadienol from 24,25-epoxy-cucurbitadienol;

wherein the polypeptide capable of synthesizing 11-hydroxy-cucurbitadienol from cucurbitadienol or 11-hydroxy-24,25-epoxy-cucurbitadienol from 24,25-epoxy-cucurbitadienol comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:44;

(d) a gene encoding a polypeptide capable of synthesizing mogrol from 11-hydroxy-24,25-epoxy-cucurbitadienol;

wherein the polypeptide capable of synthesizing mogrol from 11-hydroxy-24,25-epoxy-cucurbitadienol comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:74;

(e) a gene encoding a polypeptide capable of reducing cytochrome P450 complex; wherein the polypeptide capable of reducing cytochrome P450 complex comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:46; and

(f) a gene encoding a polypeptide capable of synthesizing the mogroside precursor from 11-hydroxy-24,25-epoxy-cucurbitadienol;

wherein the polypeptide capable of synthesizing the mogroside precursor from 11-hydroxy-24,25-epoxy-cucurbitadienol comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:38 or 40;

and further comprising:

(g) a gene encoding a polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group;

wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:22, 62, and 68;

(h) a gene encoding a polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-24 hydroxyl group;

wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-24 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:21, 22, 23, 24 25, 48, and 68;

(i) a gene encoding a polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group and C-24 hydroxyl group;

wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group and C-24 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:22 or 68;

(j) a gene encoding a polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-11 hydroxyl group;

wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-11 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:24;

(k) a gene encoding a polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose of the mogroside precursor and/or the mogroside compound;

wherein the polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose of the mogroside precursor and/or the mogroside compound comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:50, 53, 70, and 72; and

(l) a gene encoding a polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose and/or beta-1,2-glycosylation of the C6′ of the 3-O-glucose and/or the 24-O-glucose of the mogroside precursor and/or the mogroside compound;

wherein the polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose and/or beta-1,2-glycosylation of the C6′ of the 3-O-glucose and/or the 24-O-glucose of the mogroside precursor and/or the mogroside compound comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:70 or 72;

wherein at least one of the genes in items (a)-(l) is a recombinant gene.

2. The recombinant host cell of claim 1 , wherein the recombinant host cell has been modified to reduce expression of a lanosterol synthase (ERG7) polypeptide.

3. The recombinant host of claim 2 , wherein the ERG7 polypeptide comprises a polypeptide having an amino acid sequence set forth in SEQ ID NO:55.

4. The recombinant host of claim 1 , wherein one or more of the genes further comprise a nucleotide sequence coding a fusion tag.

5. The recombinant host of claim 4 , wherein the fusion tag is a protein or polypeptide.

6. The recombinant host of claim 5 , wherein the fusion tag is green fluorescent protein (GFP), human influenza hemagglutinin (HA), glutathione S transferase (GST), a polyhistidine-tag (HIS tag), and a FLAG-tag, a chloroplast transit peptide, a mitochondrial transit peptide, an amyloplast peptide, a signal peptide, or a secretion tag.

7. The recombinant host of claim 1 , wherein one or more of the genes are expressed as fusion proteins.

8. The recombinant host of claim 1 , wherein the mogrol precursor is squalene, oxidosqualene, dioxidosqualene, cucurbitadienol, 24,25 epoxy cucurbitadienol, 11-hydroxy-cucurbitadienol, 11-hydroxy 24, 25 epoxy cucurbitadienol or 11-oxo-mogrol.

9. The recombinant host of claim 1 , wherein the mogroside precursor is mogrol or a glycosylated, a di-glycosylated, a tri-glycosylated, or a tetra-glycosylated mogrol.

10. The recombinant host cell of claim 9 , wherein the tetra-glycosylated mogroside precursor is mogroside IV or siamenoside I.

11. The recombinant host cell of claim 1 , wherein the mogroside compound is a glycosylated, a di-glycosylated, a tri-glycosylated, a tetra-glycosylated, or a penta-glycosylated mogroside compound.

12. The recombinant host of claim 11 , wherein:

(a) the glycosylated mogroside compound is mogroside I A1 or mogroside I E1;

(b) the di-glycosylated mogroside compound is mogroside IIA, mogroside II A1, mogroside II A2, mogroside II E or mogroside II E1;

(c) the tri-glycosylated mogroside compound is mogroside III A1, mogroside III A2, mogroside III, or mogroside III E;

(d) the tetra-glycosylated mogroside compound is mogroside IV, mogroside IV A, or siamenoside; and

(e) the penta-glycosylated mogroside compound is mogroside V.

13. The recombinant host cell of claim 1 , wherein the recombinant host cell comprises a plant cell, a mammalian cell, an insect cell, a fungal cell, an algal cell, or a bacterial cell.

14. A method of producing a mogrol precursor, a mogroside precursor, and/or a mogroside compound, comprising growing the recombinant host cell of claim 1 in a culture medium, under conditions in which the genes are expressed;

wherein the mogrol precursor, the mogroside precursor, and/or the mogroside compound are produced by the recombinant host cell.

15. The method of claim 14 , wherein the recombinant host cell is grown in a fermentor at a temperature for a period of time, wherein the temperature and period of time facilitate the production of the mogrol precursor, the mogroside precursor, and/or the mogroside compound.

16. The method of claim 14 , further comprising isolating the mogrol precursor, the mogroside precursor, and/or the mogroside compound produced.

17. The method of claim 16 , wherein the isolating step comprises:

(a) providing the cell culture comprising the mogrol precursor, the mogroside precursor, and/or the mogroside compound;

(b) separating a liquid phase of the cell culture from a solid phase of the cell culture to obtain a supernatant comprising the mogrol precursor, the mogroside precursor, and/or the mogroside compound;

(c) providing one or more adsorbent resins, comprising providing the adsorbent resins in a packed column; and

(d) contacting the supernatant of step (b) with the one or more adsorbent resins in order to obtain at least a portion of the mogrol precursor, the mogroside precursor, and/or the mogroside compound, thereby isolating the mogrol precursor, the mogroside precursor, and/or the mogroside compound;

or

(a) providing the cell culture comprising the mogrol precursor, the mogroside precursor, and/or the mogroside compound;

(b) separating a liquid phase of the cell culture from a solid phase of the cell culture to obtain a supernatant comprising the mogrol precursor, the mogroside precursor, and/or the mogroside compound;

(c) providing one or more ion exchange or reversed-phase chromatography columns; and

(d) contacting the supernatant of step (b) with the one or more ion exchange or reversed-phase chromatography columns in order to obtain at least a portion of the mogrol precursor, the mogroside precursor, and/or the mogroside compound, thereby isolating the mogrol precursor, the mogroside precursor, and/or the mogroside compound; or

(a) providing the cell culture comprising the mogrol precursor, the mogroside precursor, and/or the mogroside compound;

(b) separating a liquid phase of the cell culture from a solid phase of the cell culture to obtain a supernatant comprising the mogrol precursor, the mogroside precursor, and/or the mogroside compound;

(c) crystallizing or extracting the mogrol precursor, the mogroside precursor, and/or the mogroside compound, thereby isolating the mogrol precursor, the mogroside precursor, and/or the mogroside compound.

18. The method of claim 14 , further comprising recovering the mogroside precursor and/or the mogroside compound, providing a mogroside composition thereby.

19. The method of claim 18 , wherein the recovered mogroside composition is enriched for the mogroside precursor and/or the mogroside compound relative to a mogroside composition from a S. grosvenorii plant; and

wherein the recovered mogroside composition has a reduced level of S. grosvenorii plant-derived components relative to a plant-derived S. grosvenorii extract.

20. A method of producing mogroside compound, comprising whole cell bioconversion of a plant-derived or a synthetic mogrol precursor or a mogroside precursor in a cell culture medium of the recombinant host cell of claim 1 using:

(a) the polypeptide capable of synthesizing oxidosqualene or dioxidosqualene from squalene;

wherein the polypeptide capable of synthesizing oxidosqualene or dioxidosqualene from squalene comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 54;

(b) the polypeptide capable of synthesizing cucurbitadienol from oxidosqualene, or 24,25-epoxy-cucurbitadienol from dioxidosqualene;

wherein the polypeptide capable of synthesizing cucurbitadienol from oxidosqualene or 24,25-epoxy-cucurbitadienol from dioxidosqualene comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 43;

(c) the polypeptide capable of synthesizing 11-hydroxy-cucurbitadienol from cucurbitadienol, or 11-hydroxy-24,25-epoxy-cucurbitadienol from 24,25-epoxy-cucurbitadienol;

wherein the polypeptide capable of synthesizing 11-hydroxy-cucurbitadienol from cucurbitadienol or 11-hydroxy-24,25-epoxy-cucurbitadienol from 24,25-epoxy-cucurbitadienol comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 44;

(d) the polypeptide capable of synthesizing mogrol from 11-hydroxy-24,25-epoxy-cucurbitadienol;

wherein the polypeptide capable of synthesizing mogrol from 11-hydroxy-24,25-epoxy-cucurbitadienol comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 74;

(e) the polypeptide capable of reducing cytochrome P450 complex;

wherein the polypeptide capable of reducing cytochrome P450 complex comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 46; and

(f) the polypeptide capable of synthesizing the mogroside precursor from 11-hydroxy-24,25-epoxy-cucurbitadienol;

wherein the polypeptide capable of synthesizing the mogroside precursor from 11-hydroxy-24,25-epoxy-cucurbitadienol comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 38 or 40;

and further comprising:

(g) the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group;

wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:22, 62, and 68;

(h) the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-24 hydroxyl group;

wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-24 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:21, 22, 23, 24 25, 48, and 68;

(i) the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group and C-24 hydroxyl group;

wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group and C-24 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:22 or 68;

(j) the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-11 hydroxyl group;

wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-11 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:24;

(k) the polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose of the mogroside precursor and/or the mogroside compound;

wherein the polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose of the mogroside precursor and/or the mogroside compound comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:50, 53, 70, or 72; and

(l) the polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose and/or beta-1,2-glycosylation of the C6′ of the 3-O-glucose and/or the 24-O-glucose of the mogroside precursor and/or the mogroside compound;

wherein the polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose and/or beta-1,2-glycosylation of the C6′ of the 3-O-glucose and/or the 24-O-glucose of the mogroside precursor and/or the mogroside compound comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:70 or 72;

wherein at least one of the polypeptides in items (a)-(l) is a recombinant polypeptide expressed in the recombinant host cell;

wherein the mogrol precursor is squalene, oxidosqualene, dioxidosqualene, cucurbitadienol, 24,25 epoxy cucurbitadienol, 11-hydroxy-cucurbitadienol, 11-hydroxy 24, 25 epoxy cucurbitadienol or 11-oxo-mogrol; and

wherein the mogroside precursor is mogrol or a glycosylated, a di-glycosylated, a tri-glycosylated, or a tetra-glycosylated mogrol;

and producing the mogroside compound.

21. An in vitro method of producing a mogroside compound, comprising adding:

(a) a polypeptide capable of synthesizing oxidosqualene or dioxidosqualene from squalene;

wherein the polypeptide capable of synthesizing oxidosqualene or dioxidosqualene from squalene comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:54;

(b) a polypeptide capable of synthesizing cucurbitadienol from oxidosqualene, or 24,25-epoxy-cucurbitadienol from dioxidosqualene;

wherein the polypeptide capable of synthesizing cucurbitadienol from oxidosqualene or 24,25-epoxy-cucurbitadienol from dioxidosqualene comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:43;

(c) a polypeptide capable of synthesizing 11-hydroxy-cucurbitadienol from cucurbitadienol, or 11-hydroxy-24,25-epoxy-cucurbitadienol from 24,25-epoxy-cucurbitadienol;

wherein the polypeptide capable of synthesizing 11-hydroxy-cucurbitadienol from cucurbitadienol or 11-hydroxy-24,25-epoxy-cucurbitadienol from 24,25-epoxy-cucurbitadienol comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:44;

(d) a polypeptide capable of synthesizing mogrol from 11-hydroxy-24,25-epoxy-cucurbitadienol;

wherein the polypeptide capable of synthesizing mogrol from 11-hydroxy-24,25-epoxy-cucurbitadienol comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:74;

(e) a polypeptide capable of reducing cytochrome P450 complex;

wherein the polypeptide capable of reducing cytochrome P450 complex comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:46; and

(f) a polypeptide capable of synthesizing the mogroside precursor from 11-hydroxy-24,25-epoxy-cucurbitadienol;

wherein the polypeptide capable of synthesizing the mogroside precursor from 11-hydroxy-24,25-epoxy-cucurbitadienol comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:38 or 40;

and further comprising:

(g) a polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group;

wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:22, 62, and 68;

(h) a polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-24 hydroxyl group;

wherein the polypeptide capable of glycosylating the mog roside precursor and/or the mogroside compound at its C-24 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:21, 22, 23, 24 25, 48, and 68;

(i) a polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group and C-24 hydroxyl group;

wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group and C-24 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:22 or 68;

(j) a polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-11 hydroxyl group;

wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-11 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:24;

(k) a polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose of the mogroside precursor and/or the mogroside compound;

wherein the polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose of the mogroside precursor and/or the mogroside compound comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:50, 53, 70, and 72; and

(l) a polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose and/or beta-1,2-glycosylation of the C6′ of the 3-O-glucose and/or the 24-O-glucose of the mogroside precursor and/or the mogroside compound;

wherein the polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose and/or beta-1,2-glycosylation of the C6′ of the 3-O-glucose and/or the 24-O-glucose of the mogroside precursor and/or the mogroside compound comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:70 or 72;

and a plant-derived ora synthetic mogrol precursor or a mogroside precursor to a reaction mixture;

wherein the mogrol precursor is squalene, oxidosqualene, dioxidosqualene, cucurbitadienol, 24,25 epoxy cucurbitadienol, 11-hydroxy-cucurbitadienol, 11-hydroxy 24,25 epoxy cucurbitadienol or 11-oxo-mogrol;

wherein the mogroside precursor is mogrol or a glycosylated, a di-glycosylated, a tri-glycosylated, or a tetra-glycosylated mogrol; and

wherein at least one of the polypeptides in items (a)-(l) is a recombinant polypeptide;

and producing the mogroside compound.

22. A method for transferring a sugar moiety to a C-3 hydroxyl group, a C-24 hydroxyl group, both the C-3 hydroxyl group and the C-24 hydroxyl group, a C2′ and/or a C6′ position of a 3-O-glucose and/or the 24-O-glucose of a mogroside precursor and/or a mogroside compound, comprising contacting the mogroside precursor and/or the mogroside compound with a recombinant polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at the C-3 hydroxyl group, wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:22, 62, and 68; the C-11 hydroxyl group, wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-11 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:24; the C-24 hydroxyl group, wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-24 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:21, 22, 23, 24 25, 48, and 68; both the C-3 hydroxyl group and the C-24 hydroxyl group, wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group and C-24 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:22 or 68; beta-1,6-glycosylation of the C2′ of the 24-O-glucose, wherein the polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose of the mogroside precursor and/or the mogroside compound comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:50, 53, 70, and 72; and/or beta-1,6-glycosylation of the C2′ of the 24-O-glucose and/or beta-1,2-glycosylation of the C6′ of the 3-O-glucose and/or the 24-O-glucose, wherein the polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose and/or beta-1,2-glycosylation of the C6′ of the 3-O-glucose and/or the 24-O-glucose of the mogroside precursor and/or the mogroside compound comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:70 or 72; and a UDP-sugar under suitable reaction conditions for the transfer of the sugar moiety to the mogroside precursor and/or the mogroside compound,

wherein the mogroside precursor is mogrol or a glycosylated, a di-glycosylated, a tri-glycosylated or a tetra-glycosylated mogrol; and

wherein a glycosylated, a di-glycosylated, a tri-glycosylated, a tetra-glycosylated, or a penta-glycosylated mogroside compound, an isomer thereof, and/or a mogroside composition thereof is produced upon transfer of the sugar moiety.

23. The method of claim 22 , wherein:

(a) the sugar moiety is glucose, and mogroside I A1 is produced upon transfer of the glucose moiety to mogrol;

(b) the sugar moiety is glucose, and mogroside I E1 is produced upon transfer of the glucose moiety to mogrol;

(c) the sugar moiety is glucose, and mogroside II E1 is produced upon transfer of the glucose moiety to mogrol;

(d) the mogroside precursor is mogroside I A1, wherein the sugar moiety is glucose, and mogroside II A is produced upon transfer of the glucose moiety;

the mogroside precursor is mogroside I A1, wherein the sugar moiety is glucose, and mogroside II A2 is produced upon transfer of the glucose moiety;

(e) the mogroside precursor is mogroside I A1, wherein the sugar moiety is glucose, and mogroside II E is produced upon transfer of the glucose moiety;

(f) the mogroside precursor is mogroside I A1, wherein the sugar moiety is glucose, and mogroside III A1 is produced upon transfer of the glucose moiety;

(g) the mogroside precursor is mogroside I E1, wherein the sugar moiety is glucose, and mogroside II E is produced upon transfer of the glucose moiety;

the mogroside precursor is mogroside I E1, wherein the sugar moiety is glucose, and mogroside II A1 is produced upon transfer of the glucose moiety;

(h) the mogroside precursor is mogroside II A, wherein the sugar moiety is glucose, and mogroside III A1 is produced upon transfer of the glucose moiety;

(i) the mogroside precursor is mogroside II E, wherein the sugar moiety is glucose, and mogroside III A1 is produced upon transfer of the glucose moiety;

(j) the mogroside precursor is mogroside II E, wherein the sugar moiety is glucose, and mogroside III A2 is produced upon transfer of the glucose moiety;

(k) the mogroside precursor is mogroside II E, wherein the sugar moiety is glucose, and mogroside III E is produced upon transfer of the glucose moiety;

(l) the mogroside precursor is mogroside II E, wherein the sugar moiety is glucose, and mogroside III is produced upon transfer of the glucose moiety;

(m) the mogroside precursor is mogroside II E, wherein the sugar moiety is glucose, and mogroside IV A is produced upon transfer of the glucose moiety;

(n) the mogroside precursor is mogroside II E, wherein the sugar moiety is glucose, and mogroside IV A is produced upon transfer of the glucose moiety;

(o) the mogroside precursor is mogroside II E, wherein the sugar moiety is glucose, and mogroside IV is produced upon transfer of the glucose moiety;

(p) the mogroside precursor is mogroside II E, wherein the sugar moiety is glucose, and mogroside V is produced upon transfer of the glucose moiety;

(q) the mogroside precursor is mogroside III E, wherein the sugar moiety is glucose, and mogroside II A2 is produced upon transfer of the glucose moiety;

(r) the mogroside precursor is mogroside III A2, wherein the sugar moiety is glucose, and mogroside IV is produced upon transfer of the glucose moiety;

(s) the mogroside precursor is mogroside III, wherein the sugar moiety is glucose, and mogroside IVA is produced upon transfer of the glucose moiety;

(t) the mogroside precursor is mogroside III A1, wherein the sugar moiety is glucose, and siamenoside 1 is produced upon transfer of the glucose moiety;

(u) the mogroside precursor is mogroside IV, wherein the sugar moiety is glucose, and siamenoside 1 is produced upon transfer of the glucose moiety; or

(v) the mogroside precursor is siamenoside 1, wherein the sugar moiety is glucose, and mogroside V is produced upon transfer of the glucose moiety.

24. The method of claim 22 , wherein mogrol or the glycosylated, the di-glycosylated, the tri-glycosylated or the tetra-glycosylated mogrol, the glycosylated, the di-glycosylated, the tri-glycosylated, the tetra-glycosylated or the penta-glycosylated mogroside compound, the isomer thereof, and/or the mogroside composition thereof is produced in a cell culture broth, the method comprising growing a recombinant host cell comprising (i) a gene encoding a polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group; wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:22, 62, and 68; (ii) a gene encoding a polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-24 hydroxyl group; wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-24 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:21, 22, 23, 24 25, 48, and 68; (iii) a gene encoding a polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group and C-24 hydroxyl group; wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-3 hydroxyl group and C-24 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:22 or 68; (iv) a gene encoding a polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-11 hydroxyl group; wherein the polypeptide capable of glycosylating the mogroside precursor and/or the mogroside compound at its C-11 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:24; (v) a gene encoding a polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose of the mogroside precursor and/or the mogroside compound; wherein the polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose of the mogroside precursor and/or the mogroside compound comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs:50, 53, 70, and 72; and/or (vi) a gene encoding a polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose and/or beta-1,2-glycosylation of the C6′ of the 3-O-glucose and/or the 24-O-glucose of the mogroside precursor and/or the mogroside compound; wherein the polypeptide capable of beta-1,6-glycosylation of the C2′ of the 24-O-glucose and/or beta-1,2-glycosylation of the C6′ of the 3-O-glucose and/or the 24-O-glucose of the mogroside precursor and/or the mogroside compound comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:70 or 72;

wherein at least one of the genes in items (i)-(vi) is a recombinant gene, under conditions in which one or more of the genes are expressed;

wherein contacting the glycosylated, the di-glycosylated, the tri-glycosylated or the tetra-glycosylated mogrol with the recombinant polypeptide comprises contacting the glycosylated, the di-glycosylated, the tri-glycosylated or the tetra-glycosylated mogrol with at least one of the polypeptides produced by the recombinant host cell.

25. A cell culture, comprising the recombinant host cell of claim 1 , the cell culture further comprising:

(a) the mogrol precursor, the mogroside precursor, and/or the mogroside compound produced by the recombinant host cell;

(b) glucose, fructose, sucrose, xylose, rhamnose, uridine diphosphate (UDP)-glucose, UDP-rhamnose, UDP-xylose, and/or N-acetyl-glucosamine; and

(c) supplemental nutrients comprising trace metals, vitamins, salts, YNB, and/or amino acids;

wherein the mogroside precursor and/or the mogroside compound is present at a concentration of at least 1 mg/liter of the cell culture;

wherein the cell culture is enriched for the mogroside precursor and/or the mogroside compound relative to a mogroside composition from a S. grosvenorii plant; and

wherein the cell culture has a reduced level of S. grosvenorii plant-derived components relative to a plant-derived S. grosvenorii extract.

26. A cell lysate from the recombinant host cell of claim 1 grown in the cell culture, wherein the cell lysate comprises:

(a) the mogrol precursor, the mogroside precursor, and/or the mogroside compound produced by the recombinant host cell;

(b) glucose, fructose, sucrose, xylose, rhamnose, uridine diphosphate (UDP)-glucose, UDP-rhamnose, UDP-xylose, and/or N-acetyl-glucosamine; and

(c) supplemental nutrients comprising trace metals, vitamins, salts, YNB, and/or amino acids;

wherein the mogroside precursor and/or the mogroside compound is present at a concentration of at least 1 mg/liter of the cell lysate.

27. The recombinant host cell of claim 1 , wherein the recombinant host cell is a Yarrowia lipolytica cell.

28. The method of claim 20 , wherein the mogroside compound is a glycosylated, a di-glycosylated, a tri-glycosylated, a tetra-glycosylated, or a penta-glycosylated mogroside compound, wherein:

(a) the glycosylated mogroside compound is mogroside I A1 or mogroside I E1;

(b) the di-glycosylated mogroside compound is mogroside IIA, mogroside II A1, mogroside II A2, mogroside II E1, or mogroside II E;

(c) the tri-glycosylated mogroside compound is mogroside III A1, mogroside III A2, mogroside III, or mogroside III E;

(d) the tetra-glycosylated mogroside compound is mogroside IV, mogroside IV A, or siamenoside; and

(e) the penta-glycosylated mogroside compound is mogroside V.

29. The method of claim 21 , wherein the mogroside compound is a glycosylated, a di-glycosylated, a tri-glycosylated, a tetra-glycosylated, or a penta-glycosylated mogroside compound, wherein:

(a) the glycosylated mogroside compound is mogroside I A1 or mogroside I E1;

(b) the di-glycosylated mogroside compound is mogroside IIA, mogroside II A1, mogroside II A2, mogroside II E1, or mogroside II E;

(c) the tri-glycosylated mogroside compound is mogroside III A1, mogroside III A2, mogroside III, or mogroside III E;

(d) the tetra-glycosylated mogroside compound is mogroside IV, mogroside IV A, or siamenoside; and

(e) the penta-glycosylated mogroside compound is mogroside V.

Assignments (2)
MERGER Recorded Jun 27, 2024
From: EVOLVA SA
To: DANSTAR FERMENT AG
Reel/Frame 067863/0857 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2020
From: HOUGHTON-LARSEN, JENS; SEMMLER, ANGELIKA; RIISHEDE HANSEN, IVER KLAVS; HANSEN, JORGEN
To: EVOLVA SA
Reel/Frame 051862/0450 →
Continuity (9)
Continuation 14504109 · Oct 1, 2014
Continuation PCTEP2013075510 · Dec 4, 2013
Provisional Application 61733220 · Dec 4, 2012
Provisional Application 62059136 · Oct 2, 2014
Provisional Application 62087726 · Dec 4, 2014
Provisional Application 62090836 · Dec 11, 2014
Provisional Application 62091895 · Dec 15, 2014
Provisional Application 62199115 · Jul 30, 2015
Related Publication 20170247735A1 · Aug 31, 2017
Cited By (2)
US 12,234,464 US 12,480,146